BCL-Xl Represents a Novel Therapeutic Target in Type 2 Mutant Calr-Driven Myeloproliferative Neoplasms

被引：0
|
作者：
Nauman, Mirielle [1 ]
Vanni, Daniele [1 ,2 ]
Arellano, Nicole [1 ,3 ]
Thao Trang Nguyen [4 ]
LaBelle, James [5 ]
Saygin, Caner [6 ]
Catricala, Silvia [7 ]
Casetti, Ilaria Carola [2 ]
Borsani, Oscar [2 ]
Rumi, Elisa [2 ]
Pietra, Daniela [8 ]
Elf, Shannon [9 ,10 ,11 ]
机构：
[1] Univ Chicago, Ben May Dept Canc Res, Chicago, IL USA
[2] Univ Pavia, Dept Mol Med, Pavia, Italy
[3] Univ Chicago, Comm Canc Biol, Chicago, IL USA
[4] Univ Chicago, Sect Hematol & Oncol, Dept Pediat, Chicago, IL USA
[5] Univ Chicago, Chicago, IL USA
[6] Univ Chicago, Hematol Oncol Sect, Dept Med, Chicago, IL USA
[7] Fdn IRCCS Policlin San Matteo, Div Hematol, Pavia, Italy
[8] Fdn IRCCS Policlin San Matteo, UOC Ematol 1, Pavia, Italy
[9] Univ Chicago, Div Biol Sci, Chicago, IL USA
[10] Univ Chicago, Ben May Dept Canc Res, Chicago, IL USA
[11] Univ Chicago, Comm Canc Biol, Chicago, IL USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-190295
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 17 条
  • [1] Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms
    Petiti, Jessica
    Lo Iacono, Marco
    Rosso, Valentina
    Andreani, Giacomo
    Jovanovski, Aleksandar
    Podesta, Marina
    Lame, Dorela
    De Gobbi, Marco
    Fava, Carmen
    Saglio, Giuseppe
    Frassoni, Francesco
    Cilloni, Daniela
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (18) : 10978 - 10986
  • [2] Glutamine Metabolism Is Altered in Myeloproliferative Neoplasms and Represents a Potential Novel Therapeutic Target
    Coen, Chad
    Yan, Jizhi
    Saygin, Caner
    Arellano, Nicole
    Nauman, Mirielle
    Zawieracz, Katarzyna
    Vanni, Daniele
    Catricala, Silvia
    Casetti, Ilaria Carola
    Borsani, Oscar
    Rumi, Elisa
    Pietra, Daniela
    Elf, Shannon
    Blaylock, Hunter
    BLOOD, 2023, 142
  • [3] Galectin-1 Fuels Monocyte-Driven Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms
    He, Fan
    Kong, Tim
    Lin, Shuyang
    Fulbright, Mary C.
    Laranjeira, Angelo B. A.
    Fisher, Daniel A. C.
    Cox, Maggie J.
    Ashworth, Katrina
    Di Paola, Jorge
    Oh, Stephen T.
    BLOOD, 2023, 142
  • [4] Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target
    J G Harb
    P Neviani
    B J Chyla
    J J Ellis
    G J Ferenchak
    J J Oaks
    C J Walker
    P Hokland
    D C Roy
    M A Caligiuri
    G Marcucci
    C S Huettner
    D Perrotti
    Leukemia, 2013, 27 : 1996 - 2005
  • [5] Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target
    Harb, J. G.
    Neviani, P.
    Chyla, B. J.
    Ellis, J. J.
    Ferenchak, G. J.
    Oaks, J. J.
    Walker, C. J.
    Hokland, P.
    Roy, D. C.
    Caligiuri, M. A.
    Marcucci, G.
    Huettner, C. S.
    Perrotti, D.
    LEUKEMIA, 2013, 27 (10) : 1996 - 2005
  • [6] Differential modulation of mutant CALR and JAK2 V617F-driven oncogenesis by HLA genotype in myeloproliferative neoplasms
    Shivarov, Velizar
    Tsvetkova, Gergana
    Micheva, Ilina
    Hadjiev, Evgueniy
    Petrova, Jasmina
    Ivanova, Anela
    Madjarova, Galia
    Ivanova, Milena
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [7] A novel Bcl-2/Bcl-XL inhibitor APG-1252-12A as a potential therapeutic strategy for gastric carcinoma
    Yan, Xianglei
    Yi, Hanjie
    Luo, Qiuyun
    Yuan, Luping
    Zhou, Suna
    Pan, Wentao
    Zhang, Lin
    Qiu, Miaozhen
    Yang, Dajun
    CANCER RESEARCH, 2019, 79 (13)
  • [8] Targeting BCL-XL with a Novel VHL-Based BCL-XL Degrader DT-2216 in Pre-Clinical JAK2-Mutant AML Post-MPN Models
    Wang, Zhe
    Zhang, Qi
    Skwarska, Anna
    Ramage, Cassandra L.
    Zheng, Guangrong
    Gritsman, Kira
    Bhalla, Kapil N.
    Pemmaraju, Naveen
    Zhou, Daohong
    Tyner, Jeffrey W.
    Konopleva, Marina Y.
    BLOOD, 2023, 142
  • [9] Discovery and therapeutic potential of novel Bcl-2/Bcl-xL small-molecule inhibitors in human breast cancer.
    Xu, L
    Wang, G
    Tang, N
    Nikolovska-Coleska, Z
    Wang, R
    Demchik, L
    Liu, M
    Zhang, M
    Roller, P
    Tomita, Y
    Yang, D
    Rae, J
    Lippman, ME
    Wang, S
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S66 - S66
  • [10] Targeting therapeutic resistance to the novel type II JAK2 inhibition in myeloproliferative neoplasms
    Ghosh, Nilabh
    SWISS MEDICAL WEEKLY, 2018, 148 : 19S - 19S
12